Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Sunitinib and Docetaxel is effective in the
treatment of advanced gastric cancer patients who had prior chemotherapy with
fluoropyrimidine and platinum.